Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12470775 | 0.87 | CNR1 (0.42) | METPDE3BPDE3ACNR1CNR2 | |
| SCHEMBL14793316 | 0.87 | CNR2 (0.40) | METPDE3BPDE3ACNR1CNR2 | |
| SCHEMBL12470769 | 0.85 | HTR3A (0.53) | METPDE3BPDE3ACA1CA2 | |
| SCHEMBL14783394 | 0.84 | MET (0.42) | METPDE3BPDE3ACNR1CNR2 | |
| SCHEMBL14784218 | 0.84 | MET (0.43) | METPDE3BPDE3ACNR1CNR2 | |
| SCHEMBL14783729 | 0.84 | HTR3A (0.45) | METSCN9ACA1CA2HTR3A | |
| SCHEMBL14793182 | 0.83 | MET (0.45) | METPDE3BPDE3ACNR1CNR2 | |
| SCHEMBL12470986 | 0.83 | MET (0.45) | METPDE3BPDE3ACNR1CNR2 | |
| SCHEMBL12470515 | 0.83 | MET (0.45) | METPDE3BPDE3ACNR1CNR2 | |
| SCHEMBL14783372 | 0.82 | MET (0.41) | METPDE3BPDE3ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2755976-B1 | 6-SUBSTITUTED 3-(QUINOLIN-6-YLTHIO)-[1,2,4]TRIAZOLO[4,3-A]PYRIDINES AS C-MET TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-9474762-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-9474762-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2016-10-25 | — | — | US | disclosed |
| US-20150250799-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-20150250799-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-9062045-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2015-06-23 | — | — | US | disclosed |
| US-9062045-B2 | Triazolopyridine compounds | NOVARTIS AG (CH) | 2015-06-23 | — | — | US | disclosed |
| EP-2755976-A1 | 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4]TRIAZOLO [4, 3 -A]PYRADINES AS TYROSINE KINASE | Novartis AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-20130245002-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| US-20130245002-A1 | Triazolopyridine Compounds | NOVARTIS AG (CH) | 2013-09-19 | — | — | US | disclosed |
| WO-2013038362-A1 | 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013038362-A1 | 6 - SUBSTITUTED 3 - (QUINOLIN- 6 - YLTHIO) - [1,2,4] TRIAZOLO [4, 3 -A] PYRADINES AS TYROSINE KINASE | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250799-A1 | Triazolopyridine Compounds | FLT3, RET, MET | MET 3/4885PDE3B 608/4885PDE3A 737/4885 |
| US-20130245002-A1 | Triazolopyridine Compounds | FLT3, RET, MET | MET 3/4885PDE3B 608/4885PDE3A 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.